EcoDrugPlus

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSCVAG00000008470
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSCVAG00000006307
Gene Symbol: CACNA2D2A
1 Cross references
213 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSCVAG00000009575
Gene Symbol: CASR
3 Cross references
203 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSCVAG00000014753
Gene Symbol: CACNA2D2
3 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSCVAG00000009890
Gene Symbol: CACNA2D3
4 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSCVAG00000019847
Gene Symbol: CACNA2D4
3 Cross references
230 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSCVAG00000000670
Gene Symbol: CACNA2D4
1 Cross references
233 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSCVAG00000000327
Gene Symbol: CACNB1
3 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSCVAG00000006849
Gene Symbol: CACNB2
3 Cross references
204 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSCVAG00000005144
Gene Symbol: CACNB3
1 Cross references
204 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSCVAG00000015659
Gene Symbol: CACNB3
3 Cross references
203 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSCVAG00000008167
Gene Symbol: CACNB4
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).